Andrew Hollman Meyer - Jan 2, 2025 Form 4 Insider Report for Janux Therapeutics, Inc. (JANX)

Signature
/s/ James Pennington, Attorney-in-Fact
Stock symbol
JANX
Transactions as of
Jan 2, 2025
Transactions value $
-$731,785
Form type
4
Date filed
1/3/2025, 05:10 PM
Previous filing
Dec 20, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction JANX Common Stock Award $0 +18K +23.23% $0.00 95.5K Jan 2, 2025 Direct F1
transaction JANX Common Stock Sale -$157K -2.92K -3.06% $53.76 92.6K Jan 2, 2025 Direct F2, F3
transaction JANX Common Stock Sale -$314K -5.77K -6.23% $54.51 86.8K Jan 2, 2025 Direct F2, F4
transaction JANX Common Stock Sale -$192K -3.44K -3.97% $55.76 83.3K Jan 2, 2025 Direct F2, F5
transaction JANX Common Stock Sale -$56.8K -1K -1.2% $56.78 82.3K Jan 2, 2025 Direct F2, F6
transaction JANX Common Stock Sale -$11.5K -200 -0.24% $57.37 82.1K Jan 2, 2025 Direct F2, F7

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction JANX Stock option (right to buy) Award $0 +63K $0.00 63K Jan 2, 2025 Common Stock 63K $53.24 Direct F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest in four equal annual installments beginning on January 1, 2026.
F2 The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 30, 2024.
F3 The weighted average sale price for the transaction reported was $53.7582 and the range of prices were between $53.20 and $54.18. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
F4 The weighted average sale price for the transaction reported was $54.5111 and the range of prices were between $54.21 and $55.14. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
F5 The weighted average sale price for the transaction reported was $55.7587 and the range of prices were between $55.24 and $56.23. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
F6 The weighted average sale price for the transaction reported was $56.7778 and the range of prices were between $56.33 and $57.32. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
F7 The weighted average sale price for the transaction reported was $57.365 and the range of prices were between $57.35 and $57.38. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
F8 25% of the shares subject to the option vest on January 1, 2026 and the balance will vest in equal monthly installments thereafter over a three year period.